Phase 1/2 Multiple Myeloma (M15-654)

A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

- ECOG PS ≤ 2
- Venetoclax and daratumumab naive
- R/R Multiple Myeloma as described in schema above

Key Endpoints

Primary Cohort 1) VenDd in t(11;14) positive R/R multiple myeloma
- Dose escalation: Safety and tolerability
- Randomized, placebo-controlled expansion:
  - Response rates (ORR, including PR or better)
  - Medical: VGPR or better

Cohort 2) VenDVd in R/R multiple myeloma
- Dose escalation: Safety and tolerability
- Single-arm, open-label expansion:
  - CR rates or better (sCR, CR)

Secondary
- Safety profile (VenDd, VenDVd)
- Pharmacokinetics of Ven, D, and V given as VenDd or VenDVd
- Time to event: PFS, DOR, TTP
- To explore MRD in the bone marrow by NGS

Venetoclax is being investigated for indications that have not been approved by Regulatory Agencies. Safety and Efficacy have not been established in unapproved indications.

To learn more about these studies, please visit https://ClinicalTrials.gov or email abbvieclinicaltrials@abbvie.com

Venetoclax is being codeveloped by AbbVie and Genentech, a member of the Roche Group, and Onyx Therapeutics, Inc., a wholly-owned subsidiary of Amgen Inc.

©2017 AbbVie Inc. North Chicago, IL 60064 A14543624 November 2017 Printed in U.S.A.